343 related articles for article (PubMed ID: 30320649)
1. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
3. Plasma-derived factors VIIa and X mixtures (Byclot
Ochi S; Takeyama M; Shima M; Nogami K
Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
[TBL] [Abstract][Full Text] [Related]
4. A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation.
Mitrophanov AY; Szlam F; Sniecinski RM; Levy JH; Reifman J
Anesth Analg; 2016 Sep; 123(3):535-46. PubMed ID: 27541717
[TBL] [Abstract][Full Text] [Related]
5. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P).
Tanaka KA; Taketomi T; Szlam F; Calatzis A; Levy JH
Anesth Analg; 2008 Mar; 106(3):732-8, table of contents. PubMed ID: 18292410
[TBL] [Abstract][Full Text] [Related]
6. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent.
Nakatomi Y; Nakashima T; Gokudan S; Miyazaki H; Tsuji M; Hanada-Dateki T; Araki T; Tomokiyo K; Hamamoto T; Ogata Y
Thromb Res; 2010 May; 125(5):457-63. PubMed ID: 20080285
[TBL] [Abstract][Full Text] [Related]
7. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
Dickneite G; Dörr B; Kaspereit F; Tanaka KA
J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
[TBL] [Abstract][Full Text] [Related]
8. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
9. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
Yada K; Fujitate N; Ogiwara K; Soeda T; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of thrombin generation in neonates undergoing cardiopulmonary bypass.
Guzzetta NA; Szlam F; Kiser AS; Fernandez JD; Szlam AD; Leong T; Tanaka KA
Br J Anaesth; 2014 Feb; 112(2):319-27. PubMed ID: 24193321
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin complex concentrate and recombinant prothrombin alone or in combination with recombinant factor X and FVIIa in dilutional coagulopathy: a porcine model.
Mitterlechner T; Innerhofer P; Streif W; Lödl M; Danninger T; Klima G; Hansson K; Fries D
J Thromb Haemost; 2011 Apr; 9(4):729-37. PubMed ID: 21255250
[TBL] [Abstract][Full Text] [Related]
12. Impact of experimental haemodilution on platelet function, thrombin generation and clot firmness: effects of different coagulation factor concentrates.
Caballo C; Escolar G; Diaz-Ricart M; Lopez-Vílchez I; Lozano M; Cid J; Pino M; Beltrán J; Basora M; Pereira A; Galan AM
Blood Transfus; 2013 Jul; 11(3):391-9. PubMed ID: 23058866
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
14. High-dose fibrinogen versus a clinically recommended dose of fresh frozen plasma for reversal of dilutional coagulopathy in an in vitro model of severe hemodilution.
Rosenthal C; Rau J; Volk T; Sander M; Ziemer S; Von Heymann C
Minerva Anestesiol; 2014 Aug; 80(8):894-903. PubMed ID: 24398441
[TBL] [Abstract][Full Text] [Related]
15. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma.
Scharling B; Nielsen GG; Klitgaard T; Skovsted TA; Møss J; Segel S; Larsen LF
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):677-84. PubMed ID: 17890956
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic correction of thrombin generation in dilution-induced coagulopathy: computational analysis based on a data set of healthy subjects.
Mitrophanov AY; Rosendaal FR; Reifman J
J Trauma Acute Care Surg; 2012 Aug; 73(2 Suppl 1):S95-S102. PubMed ID: 22847103
[TBL] [Abstract][Full Text] [Related]
17. The in vitro effects of fibrinogen concentrate, factor XIII and fresh frozen plasma on impaired clot formation after 60% dilution.
Haas T; Fries D; Velik-Salchner C; Reif C; Klingler A; Innerhofer P
Anesth Analg; 2008 May; 106(5):1360-5, table of contents. PubMed ID: 18420845
[TBL] [Abstract][Full Text] [Related]
18. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
[TBL] [Abstract][Full Text] [Related]
19. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.
Percy CL; Hartmann R; Jones RM; Balachandran S; Mehta D; Dockal M; Scheiflinger F; O'Donnell VB; Hall JE; Collins PW
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):357-67. PubMed ID: 25928274
[TBL] [Abstract][Full Text] [Related]
20. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
